Peripheral Neuropathies
Pure autonomic failure
Apr. 24, 2023
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.
Risk ratio (RR), absolute risk reduction (ARR) of adverse outcomes (conversion to clinically defined multiple sclerosis, relapse, progression, or MRI activity), and numbers needed to treat (NNT) to prevent the adverse outcomes have been calculated for the multicenter randomized controlled trials (references indicated between parenthesis in table second row) according to intention-to-treat analysis principles (patients lost to follow-up or who stopped treatment taken as adverse outcomes, if not differently reported) on 2-year results except when indicated. (Contributed by Dr. Luca Durelli.)